Open Access
Numéro
OCL
Volume 18, Numéro 1, Janvier-Février 2011
Dossier : Lipides et inflammation
Page(s) 31 - 33
Section Nutrition – Santé
DOI https://doi.org/10.1051/ocl.2011.0365
Publié en ligne 15 janvier 2011
  • Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006 ; 83 : 1505S–1519S. [PubMed] [Google Scholar]
  • Corwin RL. Effects of dietary fats on bone health in advanced age. Prostaglandins, leukotrienes, and essential fatty acids 2003 ; 68 : 379–386. [CrossRef] [PubMed] [Google Scholar]
  • Laneuville O, Breuer DK, Xu N, et al. Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)-octadecatrienoic acids from alpha-linolenic acid. The J Biol Chem 1995 ; 270 : 19330–19336. [CrossRef] [PubMed] [Google Scholar]
  • Mann V, Huber C, Kogianni G, Collins F, Noble B. The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007 ; 40 : 674–684. [CrossRef] [PubMed] [Google Scholar]
  • Ono K, Kaneko H, Choudhary S, et al. Biphasic effect of prostaglandin E2 on osteoclast formation in spleen cell cultures: role of the EP2 receptor. J Bone Miner Res 2005 ; 20 : 23–29. [CrossRef] [PubMed] [Google Scholar]
  • Ozgocmen S, Kaya H, Fadillioglu E, Aydogan R, Yilmaz Z. Role of antioxidant systems, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Mol Cell Biochem 2007 ; 295 : 45–52. [CrossRef] [PubMed] [Google Scholar]
  • Poulsen RC, Wolber FM, Moughan PJ, Kruger MC. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. Prostaglandins & Other Lipid Mediators 2008 ; 85 : 42–48. [CrossRef] [PubMed] [Google Scholar]
  • Rahman MM, Bhattacharya A, Fernandes G. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J Cell Physiol 2008 ; 214 : 201–209. [CrossRef] [PubMed] [Google Scholar]
  • Raisz LG, Alander CB, Simmons HA. Effects of prostaglandin E3 and eicosapentaenoic acid on rat bone in organ culture. Prostaglandins 1989 ; 37 : 615–625. [CrossRef] [PubMed] [Google Scholar]
  • Shen CL, Yeh JK, Rasty J, Li Y, Watkins BA. Protective effect of dietary long-chain n-3 polyunsaturated fatty acids on bone loss in gonad-intact middle-aged male rats. Br J Nutr 2006 ; 95 : 462–468. [CrossRef] [PubMed] [Google Scholar]
  • Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine & Growth Factor Reviews 2004 ; 15 : 457–475. [CrossRef] [PubMed] [Google Scholar]
  • Tsutsumi R, Xie C, Wei X, et al.. PGE2 signaling through the EP4 receptor on fibroblasts upregulates RANKL and stimulates osteolysis. J Bone Miner Res 2009 ; 24 : 1753–1762. [CrossRef] [PubMed] [Google Scholar]
  • Valverde P. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio. Curr Med Chem 2008 ; 15 : 284–304. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.